Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Hanna Ciepluch"'
Autor:
Talha Munir, Mazyar Shadman, Tadeusz Robak, Jennifer R. Brown, Brad Kahl, Paolo Ghia, Krzysztof Giannopoulos, Martin Simkovic, Anders Österberg, Luca Laurenti, Patricia Walker, Stephen Opat, Hanna Ciepluch, Richard Greil, Merit Hanna, Monica Tani, Marek Trneny, Danielle M. Brander, Ian W. Flinn, Sebastian Grosicki, Emma Verner, Alessandra Tedeschi, Sophie De Guibert, Gayane Tumyan, Kamel Laribi, Jose Antonio Garcia Marco, Jianyong LI, Tian Tian, Vanitha Ramakrishnan, Yu Liu, Andy Szeto, Jason Paik, Aileen Cohen, Constantine Tam, Wojciech Jurczak
Publikováno v:
HemaSphere, Vol 7, p e15364af (2023)
Externí odkaz:
https://doaj.org/article/7091e26a2653416c8b09960a458575a4
Autor:
John C. Byrd, Seema Ali Bhat, Farrukh Awan, Pratyush Giri, Sumita Ratnasingam, Roman Hájek, Dagmar Hess, Daniela Alves, Jan Maciej Zaucha, Annalise Shen, Elizabeth Bilotti, Jesse Mcgreivy, Wayne P. Rothbaum, Hanna Ciepluch
Publikováno v:
HemaSphere, Vol 7, p e197904a (2023)
Externí odkaz:
https://doaj.org/article/8da8cf41c62841f09bec7dcbf3d95b7f
Autor:
Constantine S. Tam, Tadeusz Robak, Paolo Ghia, Brad S. Kahl, Patricia Walker, Wojciech Janowski, David Simpson, Mazyar Shadman, Peter S. Ganly, Luca Laurenti, Stephen Opat, Monica Tani, Hanna Ciepluch, Emma Verner, Martin Šimkovič, Anders Österborg, Marek Trněný, Alessandra Tedeschi, Jason C. Paik, Sowmya B. Kuwahara, Shibao Feng, Vanitha Ramakrishnan, Aileen Cohen, Jane Huang, Peter Hillmen, Jennifer R. Brown
Publikováno v:
Haematologica, Vol 106, Iss 9 (2020)
Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma whose tumors carry deletion of chromosome 17p13.1 [del(17p)] have an unfavorable prognosis and respond poorly to standard chemoimmunotherapy. Zanubrutinib is a selective next-ge
Externí odkaz:
https://doaj.org/article/8f75524183cd439aaa1541ae95718eb4
Autor:
Monika Joks, Renata Kasza, Janusz Kloczko, Edyta Paczkowska, R. Kroll-Balcerzak, Elżbieta Patkowska, Olga Grzybowska-Izydorczyk, Monika Biernat, Ryszard Wichary, Wioletta Makowska, Joanna Gora-Tybor, Tomasz Sacha, Malgorzata Wach, Małgorzata Kopera, Marta Oller, Aleksandra Kostyra, Hanna Ciepluch, Joanna Niesiobedzka-Krezel, Joanna Wasilewska, Anna Rudkowska-Kazanowska, Magdalena Swiniarska, Grazyna Bober, Paulina Dumnicka, Witold Prejzner, Ewa Wasilewska, Tomasz Gromek, Elżbieta Szczepanek, Justyna Gil
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:405-415
Introduction: Tyrosine kinase inhibitors (TKIs) have greatly improved the treatment outcome for most patients with chronic myeloid leukemia (CML). Ponatinib is a new pan-inhibitor of TK active in resistant CML. This study aimed to evaluate the effica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edd3212de4c1c567c7d12ec8ee815f7f
https://doi.org/10.1016/j.clml.2021.11.012
https://doi.org/10.1016/j.clml.2021.11.012
Autor:
Constantine S Tam, Jennifer R Brown, Brad S Kahl, Paolo Ghia, Krzysztof Giannopoulos, Wojciech Jurczak, Martin Šimkovič, Mazyar Shadman, Anders Österborg, Luca Laurenti, Patricia Walker, Stephen Opat, Henry Chan, Hanna Ciepluch, Richard Greil, Monica Tani, Marek Trněný, Danielle M Brander, Ian W Flinn, Sebastian Grosicki, Emma Verner, Alessandra Tedeschi, Jianyong Li, Tian Tian, Lei Zhou, Carol Marimpietri, Jason C Paik, Aileen Cohen, Jane Huang, Tadeusz Robak, Peter Hillmen
Zanubrutinib is a next-generation, selective Bruton tyrosine kinase inhibitor with efficacy in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). We compared zanubrutinib with bendamustine-rituximab to determine its eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::561e4c262d70c0f906480609b1cc7bfd
https://ruj.uj.edu.pl/xmlui/handle/item/298141
https://ruj.uj.edu.pl/xmlui/handle/item/298141
Autor:
Brad S. Kahl, Krzysztof Giannopoulos, Wojciech Jurczak, Martin Šimkovič, Mazyar Shadman, Anders Österborg, Luca Laurenti, Patricia Walker, Stephen Opat, Henry Chan, Hanna Ciepluch, Richard Greil, Monica Tani, Marek Trnéný, Danielle M. Brander, Ian W. Flinn, Sebastian Grosicki, Emma Verner, Jennifer R. Brown, Paolo Ghia, Jianyong Li, Tian Tian, Lei Zhou, Carol Marimpietri, Jason C. Paik, Aileen Cohen, Tadeusz Robak, Peter Hillmen, Constantine S. Tam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b93974c671a4b362194d950665cd5f36
https://hdl.handle.net/10807/235654
https://hdl.handle.net/10807/235654
Autor:
Brad S. Kahl, Krzysztof Giannopoulos, Wojciech Jurczak, Martin Šimkovič, Mazyar Shadman, Anders Österborg, Luca Laurenti, Patricia Walker, Stephen Opat, Henry Chan, Hanna Ciepluch, Richard Greil, Monica Tani, Marek Trněný, Danielle M. Brander, Ian W. Flinn, Sebastian Grosicki, Emma Verner, Jennifer R. Brown, Paolo Ghia, Jianyong Li, Tian Tian, Lei Zhou, Carol Marimpietri, Jason C. Paik, Aileen Cohen, Tadeusz Robak, Peter Hillmen, Constantine S. Tam
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S139
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c2bd59af12e9bf206943a3825878777
https://doi.org/10.1016/s2152-2650(22)00840-0
https://doi.org/10.1016/s2152-2650(22)00840-0
Autor:
Mazyar Shadman, Krzysztof Giannopoulos, Wojciech Jurczak, Martin Šimkovič, Anders Österborg, Luca Laurenti, Patricia Walker, Stephen Opat, Henry Chan, Hanna Ciepluch, Richard Greil, Monica Tani, Marek Trněný, Danielle M. Brander, Ian W. Flinn, Sebastian Grosicki, Emma Verner, Jennifer R. Brown, Brad S. Kahl, Paolo Ghia, Jianyong Li, Tian Tian, Lei Zhou, Carol Marimpietri, Jason C. Paik, Aileen Cohen, Jane Huang, Tadeusz Robak, Peter Hillmen, Constantine S. Tam
Publikováno v:
Transplantation and Cellular Therapy. 28:S478-S479
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9274e0e68fcfb5ce88911803780b4a50
https://doi.org/10.1016/s2666-6367(22)00785-0
https://doi.org/10.1016/s2666-6367(22)00785-0
Autor:
Marek Trněný, Wojciech Janowski, Jane Huang, Monica Tani, Patricia F. Walker, David Simpson, Jennifer R. Brown, Shibao Feng, Alessandra Tedeschi, Sowmya B. Kuwahara, Anders Österborg, Stephen Opat, Mazyar Shadman, Luca Laurenti, Peter Ganly, Tadeusz Robak, Aileen Cohen, Jason C. Paik, Emma Verner, Paolo Ghia, Vanitha Ramakrishnan, Constantine S. Tam, Peter Hillmen, Martin Simkovic, Hanna Ciepluch, Brad S. Kahl
Publikováno v:
Haematologica
Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma whose tumors carry deletion of chromosome 17p13.1 [del(17p)] have an unfavorable prognosis and respond poorly to standard chemoimmunotherapy. Zanubrutinib is a selective next-ge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23c2ef70d4792659afbd88ebe13803aa
Autor:
Constantine S. Tam, Krzysztof Giannopoulos, Wojciech Jurczak, Martin Šimkovič, Mazyar Shadman, Anders Österborg, Luca Laurenti, Patricia Walker, Stephen Opat, Henry Chan, Hanna Ciepluch, Richard Greil, Monica Tani, Marek Trněný, Danielle M. Brander, Ian W. Flinn, Sebastian Grosicki, Emma Verner, Jennifer R. Brown, Brad S. Kahl, Paolo Ghia, Tian Tian, Carol Marimpietri, Jason C. Paik, Aileen Cohen, Jane Huang, Tadeusz Robak, Peter Hillmen
Publikováno v:
Blood. 138:396-396
Background: Zanubrutinib (zanu) is a selective next-generation Bruton tyrosine kinase (BTK) inhibitor designed to have high specificity for BTK and minimize off-target effects (Guo, J Med Chem 2019;62:7923-40). In a phase 1/2 study, zanu demonstrated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9c6a57ce6458639ff1d764ada43557a
https://doi.org/10.1182/blood-2021-148457
https://doi.org/10.1182/blood-2021-148457